Per Henrik Vincent
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Per Henrik Vincent has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Hans Hofstraat
Philips Research, Eindhoven, The Netherlands
2 shared publicationsMarco Janssen
Philips Research, Eindhoven, The Netherlands
2 shared publicationsMaud de Klerk-Starmans
Philips Research, Eindhoven, The Netherlands
2 shared publicationsOlof Akre
Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden
2 shared publicationsPieter Vos
Philips Research, Eindhoven, The Netherlands
2 shared publicationsRalf Hoffmann
Philips Research, Eindhoven, The Netherlands
2 shared publications
Latest Publications
- Open Access
Retrospective Validation of an Artificial Intelligence System for Diagnostic Assessment of Prostate Biopsies on the ProMort Cohort: Study Protocol
Introduction: Prostate cancer diagnosis and treatment planning depend on accurate histopathological assessment of needle biopsies, particularly through the Gleason scoring system. The inherently subjective nature of the grading creates variability between pathologists, potentially resulting in suboptimal patient management decisions. These reproducibility challenges extend beyond Gleason scoring to encompass other critical diagnostic and prognostic markers, including cancer volume quantification and detection of cribriform morphology patterns and perineural invasion. Artificial intelligence (AI) applications in digital pathology have emerged as promising solutions for enhancing diagnostic consistency and accuracy, with recent research demonstrating that automated systems can match expert-level performance in prostate biopsy evaluation. Nevertheless, comprehensive validation studies have revealed concerning limitations in model generalisability when deployed across different clinical environments and patient populations. Recent systematic reviews revealed widespread risk-of-bias limitations and insufficient external validation in AI diagnostic studies, highlighting critical needs for accumulated evidence supporting generalisability before clinical implementation. Rigorous external validation with preregistered protocols using independent datasets from diverse clinical settings remains essential to establish the reliability and safety of AI-assisted prostate pathology systems. Methods and analysis: This study protocol establishes a framework for the retrospective external validation of an AI system developed for prostate biopsy assessment, to be conducted on the case-control samples of the National Prostate Cancer Register of Sweden, ProMort study (1998-2015). The primary aim is to evaluate the AI model’s diagnostic accuracy and Gleason grading performance using completely independent datasets separate from any model development or previously used validation cohorts. The diversity of the validation samples, spanning multiple geographic regions, temporal collection periods, and reference standards, allows evaluation of model robustness across varied clinical contexts. Secondary aims encompass evaluating AI performance in cancer length estimation and detection of cribriform patterns and perineural invasion. This protocol delineates procedures for data collection, reference standard clarification, and prespecified statistical analyses, ensuring comprehensive validation and reliable performance assessment. The study design conforms to established reporting guidelines CLAIM and STARD-AI, and recognised best practices for AI validation in medical imaging. Ethics and dissemination: Data collection and usage were approved by the Swedish Regional Ethics Review Board and the Swedish Ethical Review Authority (permits 2012/1586-31/1, 2016/613-31/2, 2019-01395, 2019-05220). The study adheres to the Declaration of Helsinki principles, and findings will be made available in open access peer-reviewed publications. STRENGTHS AND LIMITATIONS: This study incorporates case-control subsamples from Sweden’s largest clinical prostate cancer database (the National Prostate Cancer Register, NPCR), capturing a broad spectrum of variation across Swedish regions. The validation dataset encompasses samples collected from 1998 to 2015, representing one of the first AI validation studies to systematically evaluate performance across such an extensive temporal range, capturing evolving histological sample preparation techniques and changing population characteristics. A consistent scanning and annotation platform during digitisation eliminates equipment-related technical variation, while standardised annotation protocols among pathologists ensure traceable and reliable reference standards. Case-control design with 50% cancer-related mortality may create spectrum and prevalence bias, limiting comparison with typical clinical populations and other AI studies. Differences between the diagnostic reporting guidelines applied to the AI model’s training data and our validation dataset may introduce systematic differences that affect the interpretation of AI-pathologist concordance measurements.
Open AccessRetrospective Validation of an Artificial Intelligence System for Diagnostic Assessment of Prostate Biopsies on the ProMort Cohort: Study Protocol
Introduction: Prostate cancer diagnosis and treatment planning depend on accurate histopathological assessment of needle biopsies, particularly through the Gleason scoring system. The inherently subjective nature of the grading creates variability between pathologists, potentially resulting in suboptimal patient management decisions. These reproducibility challenges extend beyond Gleason scoring to encompass other critical diagnostic and prognostic markers, including cancer volume quantification and detection of cribriform morphology patterns and perineural invasion. Artificial intelligence (AI) applications in digital pathology have emerged as promising solutions for enhancing diagnostic consistency and accuracy, with recent research demonstrating that automated systems can match expert-level performance in prostate biopsy evaluation. Nevertheless, comprehensive validation studies have revealed concerning limitations in model generalisability when deployed across different clinical environments and patient populations. Recent systematic reviews revealed widespread risk-of-bias limitations and insufficient external validation in AI diagnostic studies, highlighting critical needs for accumulated evidence supporting generalisability before clinical implementation. Rigorous external validation with preregistered protocols using independent datasets from diverse clinical settings remains essential to establish the reliability and safety of AI-assisted prostate pathology systems. Methods and analysis: This study protocol establishes a framework for the retrospective external validation of an AI system developed for prostate biopsy assessment, to be conducted on the case-control samples of the National Prostate Cancer Register of Sweden, ProMort study (1998-2015). The primary aim is to evaluate the AI model’s diagnostic accuracy and Gleason grading performance using completely independent datasets separate from any model development or previously used validation cohorts. The diversity of the validation samples, spanning multiple geographic regions, temporal collection periods, and reference standards, allows evaluation of model robustness across varied clinical contexts. Secondary aims encompass evaluating AI performance in cancer length estimation and detection of cribriform patterns and perineural invasion. This protocol delineates procedures for data collection, reference standard clarification, and prespecified statistical analyses, ensuring comprehensive validation and reliable performance assessment. The study design conforms to established reporting guidelines CLAIM and STARD-AI, and recognised best practices for AI validation in medical imaging. Ethics and dissemination: Data collection and usage were approved by the Swedish Regional Ethics Review Board and the Swedish Ethical Review Authority (permits 2012/1586-31/1, 2016/613-31/2, 2019-01395, 2019-05220). The study adheres to the Declaration of Helsinki principles, and findings will be made available in open access peer-reviewed publications. STRENGTHS AND LIMITATIONS: This study incorporates case-control subsamples from Sweden’s largest clinical prostate cancer database (the National Prostate Cancer Register, NPCR), capturing a broad spectrum of variation across Swedish regions. The validation dataset encompasses samples collected from 1998 to 2015, representing one of the first AI validation studies to systematically evaluate performance across such an extensive temporal range, capturing evolving histological sample preparation techniques and changing population characteristics. A consistent scanning and annotation platform during digitisation eliminates equipment-related technical variation, while standardised annotation protocols among pathologists ensure traceable and reliable reference standards. Case-control design with 50% cancer-related mortality may create spectrum and prevalence bias, limiting comparison with typical clinical populations and other AI studies. Differences between the diagnostic reporting guidelines applied to the AI model’s training data and our validation dataset may introduce systematic differences that affect the interpretation of AI-pathologist concordance measurements.
- 1 January 2024
- Published by Emerald Publishing
Chapter 14 Usability of Enhanced Decision Support and Predictive Modelling in Prostate Cancer
Publishers of Foundations and Trends, making research accessible
- 1 January 2024
- Published by Emerald Publishing
Chapter 14 Usability of Enhanced Decision Support and Predictive Modelling in Prostate Cancer
Publishers of Foundations and Trends, making research accessible
- Open Access
- 3 August 2022
- Published by BMJ in BMJ Health & Care Informatics
- Vol. 29 (1) , e100588
Effect of digital-enabled multidisciplinary therapy conferences on efficiency and quality of the decision making in prostate cancer care
Objectives To investigate the impact on efficiency and quality of preprostatectomy multidisciplinary therapy conferences (MDT) at Karolinska University Hospital related to the use of a digital solution compared with standard of care. Further, to explore whether gains in MDT efficiency and quality impact oncological or functional patient outcomes. Methods We conducted a prospective, observational study of preoperative prostate cancer MDT at Karolinska between February 2017 and March 2021, including 1329 patients. We compared efficiency and quality of the standard MDT and the MDT using the digital solution IntelliSpace Precision Medicine Multidisciplinary Team Orchestrator (ISPM) based on the previously used MDT-MODe approach. Clinical and patient-reported functional outcomes were derived from the medical records and the Swedish National Prostate Cancer Register. Results While ISPM was used during the MDT meeting, the time spent per patient was reduced by 24% (pDiscussion and conclusion To increase the value of the MDT, all data relevant for treatment decision need to be purposefully presented and compiled, which also enables secondary use of the data. The use of a digital solution during preoperative MDTs for prostate cancer decision making at Karolinska University Hospital improved the efficiency and quality of this multidisciplinary team meeting without impacting patient outcomes.
- 3 August 2022
- Published by BMJ in BMJ Health & Care Informatics
- Vol. 29 (1) , e100588
Open AccessEffect of digital-enabled multidisciplinary therapy conferences on efficiency and quality of the decision making in prostate cancer care
Objectives To investigate the impact on efficiency and quality of preprostatectomy multidisciplinary therapy conferences (MDT) at Karolinska University Hospital related to the use of a digital solution compared with standard of care. Further, to explore whether gains in MDT efficiency and quality impact oncological or functional patient outcomes. Methods We conducted a prospective, observational study of preoperative prostate cancer MDT at Karolinska between February 2017 and March 2021, including 1329 patients. We compared efficiency and quality of the standard MDT and the MDT using the digital solution IntelliSpace Precision Medicine Multidisciplinary Team Orchestrator (ISPM) based on the previously used MDT-MODe approach. Clinical and patient-reported functional outcomes were derived from the medical records and the Swedish National Prostate Cancer Register. Results While ISPM was used during the MDT meeting, the time spent per patient was reduced by 24% (pDiscussion and conclusion To increase the value of the MDT, all data relevant for treatment decision need to be purposefully presented and compiled, which also enables secondary use of the data. The use of a digital solution during preoperative MDTs for prostate cancer decision making at Karolinska University Hospital improved the efficiency and quality of this multidisciplinary team meeting without impacting patient outcomes.
- Open Access
The effect of digital-enabled multidisciplinary therapy conferences on efficiency and quality of the decision making in prostate-cancer care
Objectives: To investigate the impact on efficiency and quality of pre-prostatectomy multidisciplinary therapy conferences (MDT) at Karolinska University Hospital related to the use of a digital solution compared to standard of care. Further, to explore whether gains in MDT efficiency and quality impact oncological or functional patient outcomes. Methods: We conducted a prospective, observational study of preoperative prostate-cancer MDT at Karolinska between February 2017 and March 2021. We compared efficiency and quality of the standard MDT and the MDT using the digital solution IntelliSpace Precision Medicine Multidisciplinary Team Orchestrator (ISPM) based on the previously used MDT-MODe approach. Clinical and patient-reported functional outcomes were derived from the medical records and the Swedish National Prostate Cancer Register (NPCR). Results: While ISPM was used during the multidisciplinary therapy conference, the time spent per patient was reduced by 24 % (p<0.001) and most of the MDT-MODe items were scored significantly higher. There was a reduction in pelvic lymph-node dissection procedures in the ISPM cohort (p=0.001) and an increased proportion of unilateral nerve-sparing procedures (p=0.005), while all other outcome-related measures were not significantly different between the two patient groups. Discussion & Conclusion: To increase the value of the MDT, all data relevant for treatment decision need to be purposefully presented and compiled, which also enables secondary use of the data. The use of a digital solution during preoperative MDTs for prostate-cancer decision-making at Karolinska University Hospital improved the efficiency and quality of this multidisciplinary team meeting without impacting patient outcomes. What is already known?: Multidisciplinary therapy conferences are widely used in modern cancer care. Patients discussed in a multidisciplinary therapy conference are more likely to receive appropriate staging and treatment. The multidisciplinary therapy conference is time consuming and rarely digitalized or adequately structured. What does this paper add?: The use of a digital clinical decision support system during preoperative prostate-cancer multidisciplinary therapy conferences improved the efficiency and quality of the meetings. The introduction of this digital clinical decision support system was not associated with changes in oncological and functional outcomes after surgery.
Open AccessThe effect of digital-enabled multidisciplinary therapy conferences on efficiency and quality of the decision making in prostate-cancer care
Objectives: To investigate the impact on efficiency and quality of pre-prostatectomy multidisciplinary therapy conferences (MDT) at Karolinska University Hospital related to the use of a digital solution compared to standard of care. Further, to explore whether gains in MDT efficiency and quality impact oncological or functional patient outcomes. Methods: We conducted a prospective, observational study of preoperative prostate-cancer MDT at Karolinska between February 2017 and March 2021. We compared efficiency and quality of the standard MDT and the MDT using the digital solution IntelliSpace Precision Medicine Multidisciplinary Team Orchestrator (ISPM) based on the previously used MDT-MODe approach. Clinical and patient-reported functional outcomes were derived from the medical records and the Swedish National Prostate Cancer Register (NPCR). Results: While ISPM was used during the multidisciplinary therapy conference, the time spent per patient was reduced by 24 % (p<0.001) and most of the MDT-MODe items were scored significantly higher. There was a reduction in pelvic lymph-node dissection procedures in the ISPM cohort (p=0.001) and an increased proportion of unilateral nerve-sparing procedures (p=0.005), while all other outcome-related measures were not significantly different between the two patient groups. Discussion & Conclusion: To increase the value of the MDT, all data relevant for treatment decision need to be purposefully presented and compiled, which also enables secondary use of the data. The use of a digital solution during preoperative MDTs for prostate-cancer decision-making at Karolinska University Hospital improved the efficiency and quality of this multidisciplinary team meeting without impacting patient outcomes. What is already known?: Multidisciplinary therapy conferences are widely used in modern cancer care. Patients discussed in a multidisciplinary therapy conference are more likely to receive appropriate staging and treatment. The multidisciplinary therapy conference is time consuming and rarely digitalized or adequately structured. What does this paper add?: The use of a digital clinical decision support system during preoperative prostate-cancer multidisciplinary therapy conferences improved the efficiency and quality of the meetings. The introduction of this digital clinical decision support system was not associated with changes in oncological and functional outcomes after surgery.